These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9355542)

  • 1. False economy.
    Newstead C
    Nurs Times; 1997 Sep 24-30; 93(39):18. PubMed ID: 9355542
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics].
    Laux G; Günther W
    Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion.
    J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380
    [No Abstract]   [Full Text] [Related]  

  • 4. Czech government's move to cut drug costs sparks protests.
    Krosnar K
    BMJ; 2005 Jan; 330(7482):62. PubMed ID: 15637365
    [No Abstract]   [Full Text] [Related]  

  • 5. Atypical antipsychotics in the treatment of schizophrenia. Cost is a crucial issue.
    Duggins R; Rhinds D; Hall W
    BMJ; 2001 Apr; 322(7291):926; author reply 927-8. PubMed ID: 11302921
    [No Abstract]   [Full Text] [Related]  

  • 6. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
    Meltzer D
    J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics of schizophrenia in the 21st century.
    Hanson MA
    J Clin Psychiatry; 1999; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of schizophrenia pharmacotherapy.
    Soumerai SB; Law MR
    Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic grand rounds: systemwide costs associated with second-generation antipsychotics in the treatment of schizophrenia.
    Sernyak MJ; Rosenheck R
    Psychiatr Serv; 2004 Dec; 55(12):1361-2. PubMed ID: 15572563
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine: a new atypical antipsychotic for the treatment of schizophrenia.
    Gray R
    Ment Health Care; 1998 Jan; 1(5):163-4. PubMed ID: 9791402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome in schizophrenia: beyond symptom reduction.
    Meltzer HY
    J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New vs. old antipsychotics: the Texas experience.
    Reid WH
    J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mental health. Special agents.
    Bryan J
    Health Serv J; 1999 Jan; 109(5639):suppl 4-6. PubMed ID: 10345647
    [No Abstract]   [Full Text] [Related]  

  • 18. New antipsychotic agents: emerging clinical profiles.
    Buckley PF
    J Clin Psychiatry; 1999; 60 Suppl 1():12-7; discussion 28-30. PubMed ID: 10037165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost analysis of the strategies in the treatment of schizophrenics: the place of sustained release injectable atypical antipsychotics].
    Gasquet I; Bouhassira M; Launois R
    Encephale; 2005; 31(4 Pt 1):517-8. PubMed ID: 16389719
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacoeconomic aspects of the use of rispolept in therapy of patients with psychoses].
    Iakovlev VA; Dorovskikh IV; Belinskiĭ AV; Shcherbakov DV; Zhbrykunov VL; Martyniuk IuL
    Voen Med Zh; 2001 Mar; 322(3):54-7. PubMed ID: 11544710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.